Tag: Dallas

Poster-Symptom Management

Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: A Randomized, Multi-Center, Placebo-Controlled Clinical Trial (Study OS440-3004)

Background: Arbaclofen, the active R-enantiomer of baclofen, a racemic g-aminobutyric acid-B (GABAB) receptor agonist, has been a mainstay...

Read More

Poster-Symptom Management

Arbaclofen Extended-Release for the Treatment of Spasticity in Multiple Sclerosis: An Open-Label Safety Study (Study OS440-3005)

Background: Despite pharmacologic therapy, people with multiple sclerosis (MS) often experience spasticity, which can worsen with longer...

Read More

Poster-Symptom Management

Arbaclofen Extended-Release for Spasticity in Multiple Sclerosis: Responder Analysis of a Phase 3 Randomized, Placebo-Controlled Clinical Study OS440-3004

Background: Arbaclofen is the active R-enantiomer of racemic baclofen. Arbaclofen extended-release (ER) tablets have demonstrated efficacy...

Read More

Poster-Relapse Therapy

Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar

Background: Satralizumab reduced relapse risk vs placebo in neuromyelitis optica spectrum disorder (NMOSD) patients and had a favourable...

Read More

Poster-Multidisciplinary Care

National African American Multiple Sclerosis Registry: Advancing Equitable Care and Outcomes for African Americans with Multiple Sclerosis

Background: Historically, multiple sclerosis (MS) has been underdiagnosed among African Americans with MS (AAwMS). Recent evidence suggests...

Read More

Poster-Imaging

Prefrontal Metabolism Is Associated with Processing Speed in Multiple Sclerosis: A Calibrated fMRI Study

Background: Cognitive processing speed deficits are common in multiple sclerosis (MS). Despite this, the exact neural mechanism underlying...

Read More

Poster-Imaging

Could Cerebral Autoregulatory Collapse Explain Cognitive Impairment in MS?

Background: Cognitive impairment occurs in almost 70% of multiple sclerosis (MS) patients. The pathophysiology of this impairment is...

Read More

Poster-Disease-modifying Therapy

Real-World Safety and Effectiveness of Delayed-Release Dimethyl Fumarate in Relapsing Multiple Sclerosis Patients: Interim Results from Esteem

Background: Dimethyl fumarate (DMF) demonstrated strong efficacy and a favorable benefit–risk profile in patients with relapsing-remitting...

Read More

Poster-Disease-modifying Therapy

Olikos Study Design: Exploring Maintained Ofatumumab Efficacy in Relapsing MS Patients Who Transition from Intravenous Anti-CD20 Therapy

Background: B-cell depletion in patients with relapsing multiple sclerosis (RMS) using anti-CD20 monoclonal antibodies (mAbs) reduces...

Read More

Poster-Disease-modifying Therapy

Characterization of Peripheral Immune Cell Dynamics and Repopulation Patterns in the First 12 Months of Cladribine Tablets Treatment: Magnify-MS Study

Background: The action of cladribine tablets (CladT) on immune cells may be key for both onset and durability of its effect in people with...

Read More